Financials in USD. Standardized financial statements.
A compact view of how Mithra Pharmaceuticals S.A. turns revenue into operating income and net income.
| Metric | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $40.16M | $67.00M | $22.67M | $9.03M | $96.52M | $57.88M | $32.04M | $22.47M | $20.43M | $19.04M |
| Revenue Growth? | -40.1% | +195.6% | +151.0% | -90.6% | +66.8% | +80.6% | +42.6% | +9.9% | +7.3% | 0.0% |
| Cost of Revenue? | $34.16M | $31.56M | $26.15M | $13.33M | $8.26M | $1.57M | $2.60M | $9.03M | $10.20M | $9.99M |
| Gross Profit? | $5.99M | $35.43M | -$3.48M | -$4.30M | $88.26M | $56.30M | $29.45M | $13.44M | $10.24M | $9.05M |
| Gross Margin? | +14.9% | +52.9% | -15.4% | -47.6% | +91.4% | +97.3% | +91.9% | +59.8% | +50.1% | +47.5% |
| Operating Expenses? | $75.31M | $68.88M | $89.20M | $85.95M | $67.84M | $90.34M | $79.25M | $54.02M | $24.54M | $12.09M |
| Operating Income? | -$69.32M | -$33.44M | -$92.69M | -$90.25M | $20.42M | $14.19M | -$26.16M | -$35.98M | -$14.27M | -$2.93M |
| EBITDA? | -$52.77M | $17.46M | -$82.26M | -$80.38M | $26.19M | -$31.18M | -$47.64M | -$39.41M | -$13.59M | -$2.19M |
| Income Before Tax | -$161.79M | -$13.56M | -$126.34M | -$112.79M | -$33.01M | -$37.49M | -$51.51M | -$40.63M | -$14.62M | -$3.25M |
| Income Tax Expense | $11.71M | $46.06M | -$9.46M | -$20.70M | -$6.45M | -$9.88M | -$13.15M | -$5.55M | -$4.79M | -$293,000 |
| Net Income? | -$173.50M | -$59.62M | -$116.88M | -$92.09M | -$26.56M | -$27.61M | -$38.36M | -$35.09M | -$9.82M | -$2.96M |
| EPS? | $-2.51 | $-1.22 | $-2.69 | $-2.25 | $-0.70 | $-0.75 | $-1.17 | $-1.13 | $-0.32 | $-0.10 |
| Diluted EPS? | $-2.51 | $-1.22 | $-2.69 | $-2.25 | $-0.70 | $-0.75 | $-1.17 | $-1.13 | $-0.32 | $-0.10 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality